Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

2018203 citationsJournal Articlehybrid Open Access

Authors

The results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.

Good health and well-being

Published in: American Heart Journal

Volume 206, pp. 11-23

Field-Weighted Citation Impact: 25.01